17AAG treatment accelerates doxorubicin induced cellular senescence: Hsp90 interferes with enforced senescence of tumor cells

Drug Target Insights

Volumn 2012, Issue 6, 2012, Pages 19-39

  Sarangi, Upasana ^a   Paithankar, Khande Rao ^a   Kumar, Jonnala Ujwal ^a   Subramaniam, Vaidyanathan ^a   Sreedhar, Amere Subbarao ^a  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

17AAG; Doxorubicin; Hsp90; Neuroblastoma; Senescence

Indexed keywords

BETA GALACTOSIDASE; CALCIUM ION; CURCUMIN; DOXORUBICIN; HEAT SHOCK PROTEIN 90; RAPAMYCIN; TANESPIMYCIN;

ARTICLE; AUTOPHAGY; CANCER CELL; CELL AGING; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL NUCLEUS; CELL POPULATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; OXIDATION; OXIDATIVE STRESS; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN SYNTHESIS;

EID: 84864671645     PISSN: None     EISSN: 11773928     Source Type: Journal    
DOI: 10.4137/DTI.S9943     Document Type: Article

References (68)

1. Sreedhar AS, Csermely P. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review. Pharmacol Ther. 2004;101:227-54.
2. Whitesell L, Lindquist S. Hsp90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5:761-72.
3. Cid C, Regidor I, Poveda PD, Alcazar A. Expression of heat shock protein 90 at the cell surface in neuroblastoma cells. Cell Stress and Chaperones. 2009;14:321-7.
4. Sumizawa T, Igishu H. Release of heat shock proteins from neurblastoma cells exposed to acrylamide. J Toxicol Sci. 2008;33:117-22.
5. Kim S, Kang J, Hu W, Evans BM, Chung DH. Geldanamycin decrases Raf-1 and Akt levels and induces apotposis in neuroblastomas. Int J Cancer. 2003;103:352-9.
6. Taiyab A, Srinivas UK, Sreedhar AS. 17-(Allylamino)-17-demethoxygeldanamycin combination with diferuloylmethane selectively targets mitogen kinase pathway in a human neuroblastoma cell line. J Cancer Ther. 2010;1:197-204.
7. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003;228:111-33.
8. Sreedhar AS, Soti C, Csermely P. Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim Biophys Acta. 2004;1697: 233-42.
9. Xue C, Haber M, Flemming C, et al. p53 determines multidrug resistance of childhood neuroblastoma. Cancer Res. 2007;67:10351-60.
10. Diccianni MB, Omura-Minamisawa M, Batova A, Le T, Bridgeman L, Yu AL. Frequent deregulation of p16 and p16/G1 cell cycle-regulatory pathway in neuroblastoma. Int J Cancer. 1999;80:145-54.
11. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004;28:332-7.
12. Fulda S. Apoptosis and neuroblastoma therapy. Curr Pharma Des. 2009;9:729-37.
13. Dimri GP, Lee X, Basile G, et al. Biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92: 9363-7.
14. Kurz DJ, Decary S, Hong Y, Erusalimsky JD. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci. 2000;113:3613-22.
15. Kwak IH, Kim HS, Choi OR, Ryu MS, Lim IK. Nuclear accumulation of globular actin as a cellular senescence marker. Cancer Res. 2004;64: 572-80.
16. Lee S, Jeong SY, Lim WC, et al. Mitochondrial fission and fusion mediators, hFis1 and OPA1, modulate cellular senescence. J Biol Chem. 2007;282: 22977-83.
17. Hwang ES, Yoon G, Kang HT. A comparative analysis of the cell biology of senescence and aging. Cell Mol Life Sci. 2009;66:2503-24.
18. Shammas MA, Koley H, Batchu RB, et al. Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol Cancer. 2005;4:24.
19. Ke XS, Qu Y, Rostad K, et al. Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS ONE. 2009;4:e4687.
20. Posepelova TV, Demidenko ZN, Bukreeva EI, Pospelov VA, Gudkov AV, Blagosklonny MV. Pseudo-DNA damage in response in senescent cells. Cell Cycle. 2009;8:4112-8.
21. Beausejour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003;22:4212-22.
22. Omura-Minamisawa M, Diccianni MB, Chang RC, et al. p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. Clin Cancer Res. 2001;7: 3481-90.
23. Huang MS, Adebanjo OA, Awumey E, et al. IP(3), IP(3) receptor, and cellular senescence. Am J Physiol Renal Physiol. 2000;278:F576-84.
24. Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev. 1998;8:547-81.
25. Vayssier-Taussat M, Kreps SE, Adrie C, Ava JD, Christiani D, Polla BS. Mitochondrial Membrane Potential: A Novel Biomarker of Oxidative environmental Stress. Envir Health Perspect. 2002;110:301-5.
26. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science. 1996;273:59-63.
27. Passos JF, von Zglinicki T, Saretzki G. Mitochondrial dysfunction and cell senescence: cause or consequence? Rejuvenation Res. 2006;9:64-8.
28. Kip1. J Biol Chem. 2000;275:21960-8.
29. Achuthan S, Santhoshkumar TR, Prabhakar J, Nair SA, Pillai MR. Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J Biol Chem. 2011;286:37813-29.
30. Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst. 2010;102:1536-46.
31. Michishita E, Nakabayashi K, Ogino H, Suzuki T, Fujii M, Ayusawa D. DNA topoisomerase inhibitors induce reversible senescence in normal human fibroblasts. Biochem Biophys Res Comm. 1998;253:667-71.
32. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425:407-10.
33. Csermely P, Schnaider T, Soti C, Pohaszka Z, Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther. 1998;79:129-68.
34. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010;5:99-118.
35. Coppe JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLos Biol. 2008;6:2853-68.
36. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362: 2202-11.
37. Jyhothi D, Vanathi P, Mangala Gowri O, Rama Subba Rao V, Madhusudhan Rao J, Sreedhar AS. Diferuloylmethane augments the cytotoxic effects of piplartine isolated from Piper chaba. Toxicol In Vitro. 2009;23:1085-91.
38. Kamal A, Burrows FJ. Hsp90 inhibitors as selective anticancer drugs. Discov Med. 2004;4:277-80.
39. Sreedhar AS, Mihaly K, Pato B, et al. Hsp90 inhibition accelerates cell lysis: anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibitors involving both superoxides-and Hsp90-dependent events. J Biol Chem. 2003;278:35231-40.
40. Di Micco R, Sulli G, Dobreva M, et al. Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol. 2011;13:292-302.
41. Spallarossa P, Altieri P, Aloi C, et al. Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. Am J Physiol Heart Circ Physiol. 2009;297:H2169-81.
42. Aprelikova O, Xiong Y, Liu ET. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J Biol Chem. 1995;270:18195-7.
43. Romagosa C, Simonetti S, Lopez-Vicente L, et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene. 2011;30:2087-97.
44. Restall IJ, Lorimer IA. Induction of premature senescence by hsp90 inhibition in small cell lung cancer. PLoS One. 2010;5:e11072.
45. Dote H, Burgan WE, Camphausen K, Tofilon PJ. Inhibition of Hsp90 compromises the DNA damage response to radiation. Cancer Res. 2006;66: 9211-20.
46. Ha K, Fiskus W, Rao R, et al. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage. Mol Cancer Ther. 2011;10:1194-206.
47. Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129:823-37.
48. Noor R, Mittal, S, Iqbal J. Superoxide dismutase-applications and relevance to human diseases. Med Sci Monit. 2002;8:RA210-05.
49. Dery E, Gosselin K, Vercamer C, et al. MnSOD upregulation induces autophagic programmed cell death in senescent keratinocytes. PLoS One. 2010;5:e12712.
50. Marchi S, Giorgi C, Suski JM, et al. Mitochondria-ros crosstalk in the control of cell death and aging. J Signal Transduct. 2012:329635.
51. Jahangir A, Ozcan C, Holmuhamedov EL, Terzic A. Increased calcium vulnerability of senescent cardiac mitochondria: protective role for a mitochondrial potassium channel opener. Mech. Ageing Dev. 2001;122: 1073-86.
52. Taiyab A, Sreedhar AS, Rao CM. Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma. Biochem Pharmacol. 2009;78: 142-52.
53. Sreedhar AS, Pardhasaradhi BV, Begum Z, Khar A, Srinivas UK. Lack of heat shock response triggers programmed cell death in a rat histiocytic cell line. FEBS Lett. 1999;456:339-42.
54. Afanas'ev I. Reactive oxygen species signaling in cancer: comparison with aging. Aging Dis. 2011;2:219-30.
55. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle. 2009;8:1888-95.
56. Park WY, Cho KA, Park JS, Kim DI, Park SC. Attenuation of EGF signaling in senescent cells by caveolin. Ann N Y Acad Sci. 2001;928:79-84.
57. Ayral-Kaloustian S, Gu J, Lucas J, et al. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates. J Med Chem. 2010;53:452-9.
58. Astle MV, Hannan KM, Ng PY, et al. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene. 2012;31:1949-62.
59. Yan Q, Wajapeyee N. Exploiting cellular senescence to treat cancer and circumvent drug resistance. Cancer Biol Ther. 2010;9:166-75.
60. Shen F, Chu S, Bence AK, et al. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther. 2008;324:95-102.
61. Soti C, Sreedhar AS, Csermely P. Apoptosis, necrosis and cellular senescence: chaperone occupancy as a potential switch. Aging Cell. 2003;2:39-45.
62. Soti C, Csermely P. Molecular chaperones and the aging process. Biogerontology. 2000;1:225-33.
63. Csermely P. Chaperone overload is a possible contributor to 'civilization diseases'. Trends Genet. 2001;17:701-4.
64. Campsi J. Cancer, aging and cellular senescence. In Vivo. 2000;14:183-8.
65. Krtolica A, Parrienllo S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Nat Acad Sci U S A. 2001;98:12072-7.
66. Young AR, Narita M. SASP reflects senescence. EMBO Rep. 2009;10: 228-30.
67. Gire V, Roux P, Wynford-Thomas D, Brondello JM, Dulic V. DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J. 2004;23:2554-63.
68. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev. 2007;21:43-8.